Neuralink, Elon Musk’s company, has received official approval from the U.S. Food and Drug Administration (FDA) to conduct human trials of its innovative neural interface. The main goal of the project is to develop a device called The Blindsight, which can restore vision to people who have lost it or were born blind. This is a significant achievement, as the company previously faced challenges in obtaining approval for human experiments due to various regulatory restrictions and concerns.
According to Musk, the The Blindsight neural implant could become a revolutionary device offering hope to millions. The device is designed for people whose visual cortex remains intact. Musk states that even in cases where eyes are completely absent, the implant will be able to restore vision by transmitting visual information directly to the brain.
The development by Neuralink represents a highly humane technology that could change the lives of millions suffering from vision loss. For more information, visit Neuralink.
